Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma

Paolo A. Ascierto, Reinhard Dummer, Helen Gogas, Keith T. Flaherty, Ana Arance, Mario Mandalà, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsová, Ralf Gutzmer, Jan Willem B. de Groot, Carmen Loquai, Ashwin Gollerkeri, Michael D. Pickard, Caroline Robert